Testing for hepatitis B in dialysis patients is routine, but newer and more sensitive detection methods mean that there is sometimes confusion around viral loads and occult infection. There are frequently difficult choices surrounding isolation and treatment. Here we describe the use of HBV serology and DNA testing in decisions around patients with end-stage renal disease. We also suggest isolation decisions based on our current understanding of the virus and its infectivity.
Keywords: clinical nephrology; end-stage kidney disease; haemodialysis; hepatitis B; infectious disease.
© 2020 Asian Pacific Society of Nephrology.